BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 22057785)

  • 1. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.
    Northcott PA; Shih DJ; Remke M; Cho YJ; Kool M; Hawkins C; Eberhart CG; Dubuc A; Guettouche T; Cardentey Y; Bouffet E; Pomeroy SL; Marra M; Malkin D; Rutka JT; Korshunov A; Pfister S; Taylor MD
    Acta Neuropathol; 2012 Apr; 123(4):615-26. PubMed ID: 22057785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
    Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
    Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
    Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
    Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
    Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup-specific alternative splicing in medulloblastoma.
    Dubuc AM; Morrissy AS; Kloosterhof NK; Northcott PA; Yu EP; Shih D; Peacock J; Grajkowska W; van Meter T; Eberhart CG; Pfister S; Marra MA; Weiss WA; Scherer SW; Rutka JT; French PJ; Taylor MD
    Acta Neuropathol; 2012 Apr; 123(4):485-499. PubMed ID: 22358458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
    Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
    Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
    Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
    J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
    Wang Y; Huang J; Yin X; Xu Q; Sun Y; Yao Y; Xiong J
    Acta Neurochir (Wien); 2024 Feb; 166(1):72. PubMed ID: 38329556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastoma comprises four distinct molecular variants.
    Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
    J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
    Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
    Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
    Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
    Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
    Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
    Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
    da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
    J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.